search icon
  • Print
  • ShareThis
  • Text Size
  •  View All Comments on Evidence Based Prevention

  • Search More Comments

    HIVMA Comments on FDA's Proposed Revision of Blood Donor Criteria

    HIVMA weighed in on the FDA’s proposed revision of blood donor deferral criteria, emphasizing the importance of establishing blood donation policies that both
    ensure a safe blood supply and are scientifically grounded.

    HIVMA Supports Proposed CDC Recommendations on Male Circumcision

    HIVMA submitted public comments in support of the Centers for Disease Control and Prevention’s (CDC’s) proposed guidelines for medical providers, patients and parents regarding male circumcision. The recommendations provide a useful tool summarizing the best available scientific evidence to support informed decision-making regarding the risks and benefits of procedure.

    HIVMA Urges Change to MSM Blood Donation Ban

    HIVMA 2014 Comments on the Advisory Committee on Blood and Tissue Safety and Availability’s (ACBTSA’s) Recommendations Regarding Changes to Federal MSM Blood Donation Deferral Criteria.

    HIVMA Comment Letter in Support of New USPSTF Hep B Recommendation

    On behalf of HIVMA, Board of Directors Chair, Dr. Joel Gallant, submitted comments in support of the U.S. Preventive Services Task Force’s (USPSTF’s) proposed updated “B” rating on screening for Hepatitis B virus (HBV) infection among non-pregnant adolescents and adults.

    HIVMA Weighs in with HHS Panel Urging Updating of Blood Donor Deferral Criteria

    HIVMA Public Comments to the December 4-5, 2013 Meeting of the Advisory Committee on Blood and Tissue Safety and Availability (ACBTSA).

    HIVMA Comments on NQF HIV Measures Maintenance

    Drs. Aberg and Horberg, HIVMA’s Chair and Chair-Elect, commented to the National Quality Forum (NQF) on behalf of HIVMA regarding the NQF’s 2012 infectious diseases measures maintenance process.  The letter supports efforts to maintain a sound and reliable set of clinical quality measures for HIV/AIDS care and treatment that conforms to the most current clinical practice guidelines, and urges alignment of HIV clinical quality data collection across health care platforms and among public and private payers.

    HIVMA’s Comments on the CDC’s Proposed Updated Recommendations for HCV Screening

    HIVMA weighed in with the Centers for Disease Control and Prevention’s (CDC’s) Division of Viral Hepatitis, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention in support of the CDC’s proposed new age-based (“birth cohort”) screening guidelines for the Hepatitis C virus (“HCV”).

    HIVMA Urges Additional Research to Improve the Accuracy of Consumer Driven HIV Rapid Testing

    HIVMA urges timely reconsideration of the rapid test for approval when the accuracy of consumer driven rapid tests can be increased to at least 95%.

    Letter to NIH on Blood Donation Policy Study

    HIVMA submitted comments in support of a National Institutes of Health Proposed Study of the Current Blood Donation Policy for Men Who Have Sex with Men.

    Release of Revised CDC Screening Guidelines for Hepatitis C Virus

    HIVMA and IDSA sent a joint letter to Department of Health & Human Services, Centers for Disease Control & Prevention, and the Agency for Healthcare Research & Quality, uring the adoption of new draft hepatitis C screening guidelines that would recommend a one-time screening for all Americans born during the period 1945 to 1965.

    Comments to PCORI on Draft National Priorities for Research

    HIVMA submitted comments to the Patient-Centered Outcomes Research Institute highlighting the importance of assessing alternative approaches to preventing, diagnosing and treating HIV/AIDS and reducing associated concurrent conditions and health disparities.

    HIVMA and IDSA Comment on CDC’s Proposed Updated Organ Transplantation Guidelines

    HIVMA and IDSA filed joint public comments in response to the CDC’s proposed PHS Guideline for Reducing Transmission of Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), And Hepatitis C Virus (HCV)Through Solid Organ Transplantation.

    Letter to U.S. Preventive Services Task Force on HPTN-052

    HIVMA Board Chair, Dr. Judith A. Aberg, weighed in with the U.S. Preventive Services Task Force (USPSTF) on behalf of HIVMA, to highlight the relevance of the HPTN-052 clinical trial findings for the updated evidence review on routine HIV screening that the Task Force is currently conducting.

    HIV HCAWG urges Essential Health Benefits Package that meets the needs of people with HIV

    An essential health benefits package that provides the flexibility to cover medically-necessary services for people with HIV/AIDS to stay healthy will result in better health outcomes for people with HIV/AIDS and reduce health expenditures.

    Letter to U.S. Preventive Services Task Force Supporting Routine HIV Screening

    HIVMA compiled and submitted a preliminary review of the evidence of which we are aware published since 2007 that justifies timely action by the USPSTF.

    HIVMA Urges HHS to Accept IOM Recommendation on HIV Screening for Women

    In a letter to HHS Secretary Kathleen Sebelius, HIVMA Board Chair Kathleen Squires, MD applauded the Institute of Medicine’s inclusion of annual HIV screening for sexually active women among recommendations for women’s preventive services that should be covered free of cost-sharing.

    Preventive Services Coverage for Women

    In a letter to the IOM Committee Board on Population Health and Public Health Practice, HIVMA commented on what additional preventive services private insurers must cover for women.

    Recommendations for Strengthening the National HIVAIDS Strategy

    HIVMA and the RWMPC developed recommendations for strengthening the access to care component of the National HIV/AIDS Strategy (NHAS) and its accompanying implementation plan.


    Since the USPSTF conducted its focused update of the evidence on routine HIV screening in 2007: earlier initiation of antiretroviral treatment has become the standard of care for HIV disease; much more is known about the serious long‐term risks of delaying antiretroviral therapy; routine HIV testing programs have successfully been implemented in a variety of settings; and most states have revised their laws or regulations to support opt‐out routine HIV testing.


Average 0 out of 5

| IDSA | Contact Us

© Copyright HIVMA 2012 HIV Medicine Association

Full Site Mobile Site